"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,EP,A1,EP 3277329 A1,106-327-458-881-347,2018-02-07,2018,EP 16774062 A,2016-03-30,US 201562140820 P;;US 2016/0024896 W,2015-03-31,DELIVERY VEHICLES FOR STEM CELLS AND USES THEREOF,,UNIV NORTH CAROLINA CHAPEL HILL,HINGTGEN SHAWN D;;RODRIGUEZ BAGO JULIO;;EWEND MATTHEW G;;GIROUX KAREN J;;DUMITRU RALUCA,,https://lens.org/106-327-458-881-347,Patent Application,yes,0,0,9,9,0,A61L27/222;;A61L27/3834;;A61L27/3878;;A61L27/50;;A61L27/54;;A61L27/56;;C12N5/0012;;C12N5/0619;;C12N5/0663;;C12N2501/602;;C12N2506/1307;;C12N2510/00;;C12N2513/00;;C12N2533/56;;C12N2535/00;;C12N2502/1352;;A61L27/58;;A61P35/00;;A61P43/00;;A61L27/222;;A61L27/3834;;A61L27/3878;;A61L27/54;;A61L27/56;;A61L27/50;;C12N2501/602;;C12N2533/56;;C12N2510/00;;C12N5/0619;;C12N5/0663;;C12N2506/1307;;C12N2513/00;;C12N2502/1352;;C12N5/0012;;C12N2535/00;;A61L27/58;;A61L31/16,A61L27/58;;A61L31/16;;A61P35/00;;C12N5/0775;;C12N5/0797,,0,0,,,,DISCONTINUED
2,AU,A1,AU 2016/243612 A1,037-460-967-455-524,2017-10-12,2017,AU 2016/243612 A,2016-03-30,US 201562140820 P;;US 2016/0024896 W,2015-03-31,Delivery vehicles for stem cells and uses thereof,"Provided herein according to some embodiments is a biocompatible scaffold comprising stem cells (e.g., a pliable scaffold) suitable for intracavity administration after surgical removal of a tumor, wherein the scaffold allows the stem cells to migrate away from the scaffold and towards a cancerous or damaged tissue, wherein the stem cells are loaded with a therapeutic agent and/or a reporter molecule. Methods of forming the scaffold, and methods of use thereof, are also provided.",UNIV NORTH CAROLINA CHAPEL HILL,HINGTGEN SHAWN D;;RODRIGUEZ BAGO JULIO;;EWEND MATTHEW G;;GIROUX KAREN J;;DUMITRU RALUCA,,https://lens.org/037-460-967-455-524,Patent Application,no,0,0,9,9,0,A61L27/222;;A61L27/3834;;A61L27/3878;;A61L27/50;;A61L27/54;;A61L27/56;;C12N5/0012;;C12N5/0619;;C12N5/0663;;C12N2501/602;;C12N2506/1307;;C12N2510/00;;C12N2513/00;;C12N2533/56;;C12N2535/00;;C12N2502/1352;;A61L27/58;;A61P35/00;;A61P43/00;;A61L27/222;;A61L27/3834;;A61L27/3878;;A61L27/54;;A61L27/56;;A61L27/50;;C12N2501/602;;C12N2533/56;;C12N2510/00;;C12N5/0619;;C12N5/0663;;C12N2506/1307;;C12N2513/00;;C12N2502/1352;;C12N5/0012;;C12N2535/00;;A61L27/58;;A61L31/16,A61L27/58;;A61L31/16;;A61P35/00;;C12N5/0775;;C12N5/0797,,0,0,,,,DISCONTINUED
3,EP,A4,EP 3277329 A4,080-732-012-081-924,2018-12-05,2018,EP 16774062 A,2016-03-30,US 201562140820 P;;US 2016/0024896 W,2015-03-31,DELIVERY VEHICLES FOR STEM CELLS AND USES THEREOF,,UNIV NORTH CAROLINA CHAPEL HILL,HINGTGEN SHAWN D;;RODRIGUEZ BAGO JULIO;;EWEND MATTHEW G;;GIROUX KAREN J;;DUMITRU RALUCA,,https://lens.org/080-732-012-081-924,Search Report,no,3,0,9,9,0,A61L27/222;;A61L27/3834;;A61L27/3878;;A61L27/50;;A61L27/54;;A61L27/56;;C12N5/0012;;C12N5/0619;;C12N5/0663;;C12N2501/602;;C12N2506/1307;;C12N2510/00;;C12N2513/00;;C12N2533/56;;C12N2535/00;;C12N2502/1352;;A61L27/58;;A61P35/00;;A61P43/00;;A61L27/222;;A61L27/3834;;A61L27/3878;;A61L27/54;;A61L27/56;;A61L27/50;;C12N2501/602;;C12N2533/56;;C12N2510/00;;C12N5/0619;;C12N5/0663;;C12N2506/1307;;C12N2513/00;;C12N2502/1352;;C12N5/0012;;C12N2535/00;;A61L27/58;;A61L31/16,A61L27/58;;A61L31/16;;A61P35/00;;C12N5/0775;;C12N5/0797,,4,1,023-935-336-574-314,10.1002/jbm.a.35290;;25046856,"BAO-LING DU ET AL: ""Graft of the gelatin sponge scaffold containing genetically-modified neural stem cells promotes cell differentiation, axon regeneration, and functional recovery in rat with spinal cord transection : In Gs Scaffold Grafted In Spinal Cord Injury"", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH. PART A, vol. 103, no. 4, 7 August 2014 (2014-08-07), HOBOKEN, NY, US, pages 1533 - 1545, XP055516895, ISSN: 1549-3296, DOI: 10.1002/jbm.a.35290;;DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 2013, CHEN Y F ET AL: ""Neurotrophin-3 stimulates migration of mesenchymal stem cells overexpressing TrkC."", XP002785817, Database accession no. NLM23746279;;DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2001, NAKAMURA M ET AL: ""Transplantation of neural stem cells promote axonal growth and functional recovery after spinal cord injury in neonatal rats"", XP002785818, Database accession no. PREV200100519947;;See also references of WO 2016160918A1",DISCONTINUED
4,US,A1,US 2018/0064854 A1,013-934-090-228-915,2018-03-08,2018,US 201615559596 A,2016-03-30,US 201615559596 A;;US 201562140820 P;;US 2016/0024896 W,2015-03-31,DELIVERY VEHICLES FOR STEM CELLS AND USES THEREOF,"Provided herein according to some embodiments is a biocompatible scaffold comprising stem cells (e.g., a pliable scaffold) suitable for intracavity administration after surgical removal of a tumor, wherein the scaffold allows the stem cells to migrate away from the scaffold and towards a cancerous or damaged tissue, wherein the stem cells are loaded with a therapeutic agent and/or a reporter molecule. Methods of forming the scaffold, and methods of use thereof, are also provided.",UNIV NORTH CAROLINA CHAPEL HILL,HINGTGEN SHAWN D;;RODRIGUEZ BAGO JULIO;;EWEND MATTHEW G;;GIROUX KAREN J;;DUMITRU RALUCA,,https://lens.org/013-934-090-228-915,Patent Application,yes,0,3,9,9,0,A61L27/222;;A61L27/3834;;A61L27/3878;;A61L27/50;;A61L27/54;;A61L27/56;;C12N5/0012;;C12N5/0619;;C12N5/0663;;C12N2501/602;;C12N2506/1307;;C12N2510/00;;C12N2513/00;;C12N2533/56;;C12N2535/00;;C12N2502/1352;;A61L27/58;;A61P35/00;;A61P43/00;;A61L27/222;;A61L27/3834;;A61L27/3878;;A61L27/54;;A61L27/56;;A61L27/50;;C12N2501/602;;C12N2533/56;;C12N2510/00;;C12N5/0619;;C12N5/0663;;C12N2506/1307;;C12N2513/00;;C12N2502/1352;;C12N5/0012;;C12N2535/00;;A61L27/58;;A61L31/16,A61L27/58;;A61L27/22;;A61L27/38;;A61L27/54;;A61L27/56;;A61L31/16,,0,0,,,,ACTIVE
5,CA,A1,CA 2978109 A1,142-589-393-695-230,2016-10-06,2016,CA 2978109 A,2016-03-30,US 201562140820 P;;US 2016/0024896 W,2015-03-31,DELIVERY VEHICLES FOR STEM CELLS AND USES THEREOF,"Provided herein according to some embodiments is a biocompatible scaffold comprising stem cells (e.g., a pliable scaffold) suitable for intracavity administration after surgical removal of a tumor, wherein the scaffold allows the stem cells to migrate away from the scaffold and towards a cancerous or damaged tissue, wherein the stem cells are loaded with a therapeutic agent and/or a reporter molecule. Methods of forming the scaffold, and methods of use thereof, are also provided.",UNIV NORTH CAROLINA CHAPEL HILL,HINGTGEN SHAWN D;;RODRIGUEZ BAGO JULIO;;EWEND MATTHEW G;;GIROUX KAREN J;;DUMITRU RALUCA,,https://lens.org/142-589-393-695-230,Patent Application,no,0,0,9,9,0,A61L27/222;;A61L27/3834;;A61L27/3878;;A61L27/50;;A61L27/54;;A61L27/56;;C12N5/0012;;C12N5/0619;;C12N5/0663;;C12N2501/602;;C12N2506/1307;;C12N2510/00;;C12N2513/00;;C12N2533/56;;C12N2535/00;;C12N2502/1352;;A61L27/58;;A61P35/00;;A61P43/00;;A61L27/222;;A61L27/3834;;A61L27/3878;;A61L27/54;;A61L27/56;;A61L27/50;;C12N2501/602;;C12N2533/56;;C12N2510/00;;C12N5/0619;;C12N5/0663;;C12N2506/1307;;C12N2513/00;;C12N2502/1352;;C12N5/0012;;C12N2535/00;;A61L27/58;;A61L31/16,A61L27/58;;A61L31/16;;A61P35/00;;C12N5/0775;;C12N5/0797,,0,0,,,,DISCONTINUED
6,CN,A,CN 107405428 A,186-447-032-599-860,2017-11-28,2017,CN 201680019879 A,2016-03-30,US 201562140820 P;;US 2016/0024896 W,2015-03-31,DELIVERY VEHICLES FOR STEM CELLS AND USES THEREOF,"Provided herein according to some embodiments is a biocompatible scaffold comprising stem cells (e.g., a pliable scaffold) suitable for intracavity administration after surgical removal of a tumor, wherein the scaffold allows the stem cells to migrate away from the scaffold and towards a cancerous or damaged tissue, wherein the stem cells are loaded with a therapeutic agent and/or a reporter molecule. Methods of forming the scaffold, and methods of use thereof, are also provided.",UNIV NORTH CAROLINA CHAPEL HILL,HINGTGEN SHAWN D;;RODRIGUEZ BAGO JULIO;;EWEND MATTHEW G;;GIROUX KAREN J;;DUMITRU RALUCA,,https://lens.org/186-447-032-599-860,Patent Application,no,4,5,9,9,0,A61L27/222;;A61L27/3834;;A61L27/3878;;A61L27/50;;A61L27/54;;A61L27/56;;C12N5/0012;;C12N5/0619;;C12N5/0663;;C12N2501/602;;C12N2506/1307;;C12N2510/00;;C12N2513/00;;C12N2533/56;;C12N2535/00;;C12N2502/1352;;A61L27/58;;A61P35/00;;A61P43/00;;A61L27/222;;A61L27/3834;;A61L27/3878;;A61L27/54;;A61L27/56;;A61L27/50;;C12N2501/602;;C12N2533/56;;C12N2510/00;;C12N5/0619;;C12N5/0663;;C12N2506/1307;;C12N2513/00;;C12N2502/1352;;C12N5/0012;;C12N2535/00;;A61L27/58;;A61L31/16,A61L27/58;;A61L31/16;;A61P35/00;;C12N5/0775;;C12N5/0797,,4,3,005-156-575-829-366;;040-483-665-397-39X;;150-256-793-463-863,23776140;;10.1002/jbm.a.34835;;22306021;;10.1016/j.biomaterials.2012.01.037;;pmc3445432;;22980985;;10.1016/j.cell.2012.08.020,"BAO-LING DU ET AL: ""A comparative study of gelatin sponge scaffolds and PLGA scaffolds transplanted to completely transected spinal cord of rat"", 《JOURNAL OF BIOMEDICAL MATERIALS RESEARCH A》;;YINGHUI ZHONG ET AL: ""Biomaterials for the central nervous system"", 《JOURNAL OF THE ROYAL SOCIETY INTERFACE》;;TECK CHUAN LIM ET AL: ""The effect of injectable gelatin-hydroxyphenylpropionic acid hydrogel matrices on the proliferation, migration, differentiation and oxidative stress resistance of adult neural stem cells"", 《BIOMATERIALS》;;PAUL LU ET AL: ""Long-Distance Growth and Connectivity of Neural Stem Cells after Severe Spinal Cord Injury"", 《CELL》",DISCONTINUED
7,US,B2,US 11027047 B2,105-808-691-332-214,2021-06-08,2021,US 201615559596 A,2016-03-30,US 201615559596 A;;US 201562140820 P;;US 2016/0024896 W,2015-03-31,Delivery vehicles for stem cells and uses thereof,"Provided herein according to some embodiments is a biocompatible scaffold comprising stem cells (e.g., a pliable scaffold) suitable for intracavity administration after surgical removal of a tumor, wherein the scaffold allows the stem cells to migrate away from the scaffold and towards a cancerous or damaged tissue, wherein the stem cells are loaded with a therapeutic agent and/or a reporter molecule. Methods of forming the scaffold, and methods of use thereof, are also provided.",UNIV NORTH CAROLINA CHAPEL HILL,HINGTGEN SHAWN D;;RODRIGUEZ BAGO JULIO;;EWEND MATTHEW G;;GIROUX KAREN J;;DUMITRU RALUCA,,https://lens.org/105-808-691-332-214,Granted Patent,yes,56,0,9,9,0,A61L27/222;;A61L27/3834;;A61L27/3878;;A61L27/50;;A61L27/54;;A61L27/56;;C12N5/0012;;C12N5/0619;;C12N5/0663;;C12N2501/602;;C12N2506/1307;;C12N2510/00;;C12N2513/00;;C12N2533/56;;C12N2535/00;;C12N2502/1352;;A61L27/58;;A61P35/00;;A61P43/00;;A61L27/222;;A61L27/3834;;A61L27/3878;;A61L27/54;;A61L27/56;;A61L27/50;;C12N2501/602;;C12N2533/56;;C12N2510/00;;C12N5/0619;;C12N5/0663;;C12N2506/1307;;C12N2513/00;;C12N2502/1352;;C12N5/0012;;C12N2535/00;;A61L27/58;;A61L31/16,A61L27/58;;A61L27/22;;A61L27/38;;A61L27/50;;A61L27/54;;A61L27/56;;A61L31/16;;C12N5/00;;C12N5/0775;;C12N5/0793,,48,30,070-725-758-650-881;;150-256-793-463-863;;040-483-665-397-39X;;014-055-914-340-682;;023-935-336-574-314;;030-640-011-017-179;;047-257-959-362-765;;115-476-205-721-594;;003-746-789-660-858;;052-003-436-165-851;;086-716-444-888-842;;153-322-040-966-433;;081-410-271-711-630;;037-275-030-178-906;;090-361-317-418-084;;021-142-528-654-359;;039-259-193-152-527;;014-925-659-513-203;;047-800-744-183-366;;013-725-508-552-19X;;083-637-858-837-565;;048-826-891-025-685;;021-804-912-785-951;;060-198-216-265-618;;088-889-326-163-865;;059-627-596-918-824;;015-844-671-496-671;;009-888-880-040-598;;006-893-490-454-485;;052-271-645-851-736,12695076;;10.1016/s0142-9612(02)00618-x;;pmc3445432;;22980985;;10.1016/j.cell.2012.08.020;;22306021;;10.1016/j.biomaterials.2012.01.037;;10.1098/rsif.2008.0071;;18477539;;pmc2475552;;10.1002/jbm.a.35290;;25046856;;23746279;;10.2174/0929867311320240007;;20617130;;pmc2899455;;10.7150/ijbs.6.371;;27133794;;10.1016/j.stem.2016.03.020;;pmc4864020;;10.1016/j.mcn.2009.12.002;;20026276;;26830441;;pmc4740908;;10.1038/ncomms10593;;pmc6719790;;28148846;;10.1126/scitranslmed.aah6510;;25458894;;10.1016/j.stemcr.2014.10.008;;pmc4264063;;10.1038/nn.3019;;22197831;;pmc3601490;;10.1073/pnas.1121003109;;pmc3289376;;22308465;;22467474;;10.1002/stem.1091;;pmc3399516;;10.1016/j.stem.2012.05.018;;22683203;;10.1016/j.stem.2012.03.003;;22445518;;10.1016/j.gpb.2013.09.003;;pmc3908478;;24076032;;10.1093/neuonc/nou255.2;;20521177;;10.1007/s12015-010-9154-1;;10.1007/978-94-007-4798-2_7;;10.1038/gt.2008.41;;18369324;;pmc3864887;;23658244;;10.1126/scitranslmed.3005365;;20886386;;pmc2958255;;22824792;;10.1038/onc.2012.304;;pmc3676868;;10.1016/j.stem.2012.02.021;;22445517;;19001440;;10.1158/1535-7163.mct-08-0640;;pmc2748233;;10.1007/s10495-013-0925-4;;pmc3945673;;24158598;;10.1073/pnas.0806647106;;19264968;;pmc2660771;;10.1016/j.biomaterials.2010.07.075;;20709390,"Bensaid et al., Biomaterials 24: 2497-2502 (2003).;;Lu et al., Cell 150: 1264-1273 (2012).;;https://en.wikipedia.org/wiki/Thrombin, accessed Mar. 19, 2020.;;Lim et al., Biomaterials 33: 3446-3455 (2012).;;Zhong et al., J. R. Soc. Interface 5: 957-975 (2008).;;Bao-Ling et al “Graft of the gelatin sponge scaffold containing genetically-modified neural stem cells promotes cell differentiation, axon regeneration, and functional recovery in rat with spinal cord transection” Journal of Biomedical Materials Research, 103A(4):1533-1545 (2015).;;Database BIOSIS: Biosciences Information Service, Nakamura et al. “Transplantation of neural stem cells promote axonal growth and functional recovery after spinal cord injury in neonatal rats” 27(1):962 (2001).;;Database MEDLINE: US Nabonal Library of Medicine, Chen et al. “Neurotrohpin-3 stimulates migration of mesenchymal stem cells Overexpressing TrkC” Current Medicinal Chemistry, 20(24):3022-3033 (2013).;;European Search Report corresponding to European Patent Application No. 16774062.0, dated Oct. 29, 2018, 12 pages.;;International Search Report and Written Opinion, PCT/US2016/024896, dated Aug. 14, 2016.;;Singh D et al. Proliferation of myoblast skeletal cells on three-dimensional supermacroporous cryogels. International Journal of Biological Sciences. 2010; 6(4): 371-381.;;Zhang M et al. Pharmacological reprogramming of fibroblasts into neural stem cells by signaling-directed transcriptional activation. Cell Stem Cell. May 5, 2016; 18: 653-687.;;European Search Report and Opinion, EP16759479, dated Jul. 18, 2018, 6 pages.;;Onorati M et al. Neuropotent self-renewing neural stem (NS) cells derived from mouse induced pluripotent stem (iPS) cells, Molecular and Cellular Neuroscience. 2010; 43: 297-295.;;Bago Jr et al. “Neural stem cell therapy for cancer” Methods (http://dx.doi.org/10.1016/j.ymeth.2015.08.013. 7 pp (2015).;;Bago Jr et al. Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma. Nature Communications. Feb. 2, 2016; 7:10593; 1-13.;;Bago Jr et al. Tumor-homing cytotoxic human induced neural stem cells for cancer therapy. Science Translational Medicine. Feb. 1, 2017; 9: 1-13.;;Castano J et al. Fast and Efficient Neural Conversion of Human Hematopoietic Cells. Stem Cell Reports. Dec. 9, 2014; 3(6): 1118-1131.;;International Search Report and Written Opinion, PCT/US2016/020649, dated Jun. 30, 2016.;;Kauer TM et al. Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat Neurosci. Dec. 25, 2011; 15(2): 197-204.;;Lujan E et al. Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. PNAS. Feb. 14, 2012; 109(7): 2527-2532.;;Matsui T et al. Neural stem cells directly differentiated from partially reprogrammed fibroblasts rapidly acquire gliogenic competency. Stem Cells. 2012; 30: 1109-1119.;;Ring KL et al. Drect reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell. Jul. 6, 2012; 11: 100-109.;;Thier M et al. Direct conversion of fibroblasts into stably expandable neural stem cells. Cell Stem Cell. Apr. 6, 2012; 10: 437-479.;;Extended Europeen Search Report, European Patent Application No. 16759479, dated Jul. 20, 2018, 7 pages.;;Xi G. et al., Induced Neural Stem Cells Generated from Rat Fibroblasts, Genomics Proteomics Bioinformatics , Sep. 27, 2013, vol. 11, No. 5, pp. 312-319.;;Alfonso-Pecchio A. et al., Therapeutically engineered induced neural stem cells are tumor-homing and inhibit progression of glioblastorna. Neuro-Oncology, Nov. 7, 2014, vol. 16, No. SUPPL, 5. Abstract.;;Kim, S.U. “Neural stem cell-based gene therapy for brain tumors” Stem Cell Rev., Mar. 7, 2011, vol. 7, No. 1, pp. 130-140, Abstract.;;Search Report and Written Opinion, Singapore Application No. 11201707047V, dated Aug. 20, 2018, 10 pages.;;Ries et al. “Human Mesenchymal Stem Cell Transdifferentiation to Neural Cells: Role of Tumor Necrosis Factor Alpha,” Stem Cells and Cancer Stem Cells, 8:71-78 (2012) Abstract only.;;Notification Concerning Transmittal of International Preliminary Report on Patentability (Chapter I of the Patent Cooperation Treaty) PCT/US2016/020649, dated Sep. 14, 2017 (6 pages).;;Notification Concerning Transmittal of International Preliminary report on Patentability (Chapter I of the Patent Cooperation Treaty), PCT/US2016/024896, dated Oct. 12, 2017 (8 pages).;;Aboody et al. “Stem and progenitor cell-mediated tumor selective gene therapy.” Gene Therapy, 15:739-752 (2008).;;Aboody et al. “Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies,” Science Translational Medicine, 5, 13 pages (2013).;;Ahmed et al. “The use of neural stem cells in cancer gene therapy: predicting the path to the clinic,” Current Opinion in Molecular Therapeutics, 12:546-552 (2010).;;Bagci-Onder et al. “Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors,” Oncogene, 6;32(23):2818-27 (2013).;;Gelfoam® absorbable gelatine compressed sponge, USP. Physician Prescribing Information, Pfizer, Inc. Retrieved from the internet Aug. 29, 2018.;;Han D. W. et al., Direct reprogramming of fibroblasts into neural stem cells by defined factors. Cell Stem Cell., vol. 10, No. 4, pp. 465-472, Mar. 22, 2012.;;Hingtgen et al. “Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide,” Mol Cancer Ther. 7(11):3575-85 (2008).;;Ivanov et al. “A role for TRAIL/TRAIL-R2 in radiation-induced apoptosis and radiation-induced bystander response of human neural stem cells,” Apoptosis. 19(3):399-413 (2014).;;Sasportas et al. “Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy,” PNAS 106(12):4822-7 (2009).;;STEMdiff SMADi Neural Induction Kit, medium and supplement product informatioon sheet. STEMCELL Technologies, Copyright 2017, Retrieved from the internet Aug. 29, 2018.;;STEMdiff Neural Progenitor Medium, product information sheet, STEMCELL Technologies, Copyright 2016. Retrieved from the internet Aug. 29, 2018.;;TISSEEL Fibrin Sealant Physician Prescribing Information, Baxter Healthcare Corporation, Retrieved from the internet Aug. 29, 2018.;;Chinese Office Action corresponding to CN 201680019879.1, dated Nov. 28, 2019 (29 pp, including English translation).;;Japanese Office Action corresponding to JP 2017-550734; dated Jan. 24, 2020 (9 pages, including English translation).;;European Search Report corresponding to EP16774062.0, dated Oct. 4, 2019 (6 pp).;;Wang et al. “The role of stiffness of gelatin—hydroxyphenylpropionic acid hydrogels formed by enzyme-mediated crosslinking on the differentiation of human mesenchymal stem cell” Biomaterials, 31(33):8608-8616 (2010).",ACTIVE
8,WO,A1,WO 2016/160918 A1,183-737-608-284-99X,2016-10-06,2016,US 2016/0024896 W,2016-03-30,US 201562140820 P,2015-03-31,DELIVERY VEHICLES FOR STEM CELLS AND USES THEREOF,"Provided herein according to some embodiments is a biocompatible scaffold comprising stem cells (e.g., a pliable scaffold) suitable for intracavity administration after surgical removal of a tumor, wherein the scaffold allows the stem cells to migrate away from the scaffold and towards a cancerous or damaged tissue, wherein the stem cells are loaded with a therapeutic agent and/or a reporter molecule. Methods of forming the scaffold, and methods of use thereof, are also provided.",UNIV NORTH CAROLINA CHAPEL HILL,HINGTGEN SHAWN D;;RODRIGUEZ BAGO JULIO;;EWEND MATTHEW G;;GIROUX KAREN J;;DUMITRU RALUCA,,https://lens.org/183-737-608-284-99X,Patent Application,yes,3,5,9,9,0,A61L27/222;;A61L27/3834;;A61L27/3878;;A61L27/50;;A61L27/54;;A61L27/56;;C12N5/0012;;C12N5/0619;;C12N5/0663;;C12N2501/602;;C12N2506/1307;;C12N2510/00;;C12N2513/00;;C12N2533/56;;C12N2535/00;;C12N2502/1352;;A61L27/58;;A61P35/00;;A61P43/00;;A61L27/222;;A61L27/3834;;A61L27/3878;;A61L27/54;;A61L27/56;;A61L27/50;;C12N2501/602;;C12N2533/56;;C12N2510/00;;C12N5/0619;;C12N5/0663;;C12N2506/1307;;C12N2513/00;;C12N2502/1352;;C12N5/0012;;C12N2535/00;;A61L27/58;;A61L31/16,A61L27/58;;A61L31/16;;A61P35/00;;C12N5/0775;;C12N5/0797,,2,1,047-257-959-362-765,20617130;;pmc2899455;;10.7150/ijbs.6.371,"SINGH D. ET AL.: ""Proliferation of myoblast skeletal cells on three-dimensional supermacroporous cryogels"", INT J BIOL SCI., vol. 6, no. 4, 3 July 2010 (2010-07-03), pages 371 - 381, XP055317910;;See also references of EP 3277329A4",PENDING
9,AU,A,AU 1997/048182 A,008-711-182-707-172,1998-05-11,1998,AU 1997/048182 A,1997-10-15,US 73159796 A;;US 9718455 W,1996-10-16,Cytokine enhanced immunotherapy for brain tumors,,UNIV JOHNS HOPKINS,BREM HENRY;;PARDOLL DREW M;;THOMPSON REID C;;JAFFEE ELIZABETH M;;LEONG KAM W;;EWEND MATTHEW G,,https://lens.org/008-711-182-707-172,Patent Application,no,0,0,5,5,0,A61K9/0085;;A61K39/0011;;A61K48/00;;A61P35/00;;A61K39/0011,A61K9/50;;A61K9/00;;A61K35/12;;A61K38/00;;A61K39/00;;A61K47/30;;A61K48/00;;A61P35/00,,0,0,,,,PENDING
10,CA,A1,CA 2267977 A1,137-917-020-580-886,1998-04-23,1998,CA 2267977 A,1997-10-15,US 73159796 A;;US 9718455 W,1996-10-16,CYTOKINE ENHANCED IMMUNOTHERAPY FOR BRAIN TUMORS,"A therapy for treatment of patients with cancer utilizing the combination of a cytokine in a pharmaceutically acceptable carrier for systemic administration and a cytokine in a pharmaceutically acceptable carrier for local administration is described. In the most preferred embodiment, brain tumors are treated with a cytokine such as GM-CSF administered systemically, most preferably in combination with tumor antigen such as replication incompetent tumor cells, and a cytokine such as IL-2 or IL-4 administered locally, most preferably in a vehicle providing release over a period of time, such as transduced cells, again most preferably replication incompetent tumor cells, or incorporated into microparticulate vehicles such as polymeric microspheres.",UNIV JOHNS HOPKINS,EWEND MATTHEW G;;BREM HENRY;;THOMPSON REID C;;PARDOLL DREW M;;JAFFEE ELIZABETH M;;LEONG KAM W,,https://lens.org/137-917-020-580-886,Patent Application,no,0,0,5,5,0,A61K9/0085;;A61K39/0011;;A61K48/00;;A61P35/00;;A61K39/0011,A61K9/50;;A61K9/00;;A61K35/12;;A61K38/00;;A61K39/00;;A61K47/30;;A61K48/00;;A61P35/00,,0,0,,,,DISCONTINUED
11,EP,A1,EP 0930892 A1,161-963-230-935-603,1999-07-28,1999,EP 97910921 A,1997-10-15,US 9718455 W;;US 73159796 A,1996-10-16,CYTOKINE ENHANCED IMMUNOTHERAPY FOR BRAIN TUMORS,,UNIV JOHNS HOPKINS,BREM HENRY;;PARDOLL DREW M;;THOMPSON REID C;;JAFFEE ELIZABETH M;;LEONG KAM W;;EWEND MATTHEW G,,https://lens.org/161-963-230-935-603,Patent Application,yes,0,7,5,5,0,A61K9/0085;;A61K39/0011;;A61K48/00;;A61P35/00;;A61K39/0011,A61K9/50;;A61K9/00;;A61K35/12;;A61K38/00;;A61K39/00;;A61K47/30;;A61K48/00;;A61P35/00,,0,0,,,,DISCONTINUED
12,WO,A1,WO 1998/016246 A1,171-824-589-278-331,1998-04-23,1998,US 9718455 W,1997-10-15,US 73159796 A,1996-10-16,CYTOKINE ENHANCED IMMUNOTHERAPY FOR BRAIN TUMORS,"A therapy for treatment of patients with cancer utilizing the combination of a cytokine in a pharmaceutically acceptable carrier for systemic administration and a cytokine in a pharmaceutically acceptable carrier for local administration is described. In the most preferred embodiment, brain tumors are treated with a cytokine such as GM-CSF administered systemically, most preferably in combination with tumor antigen such as replication incompetent tumor cells, and a cytokine such as IL-2 or IL-4 administered locally, most preferably in a vehicle providing release over a period of time, such as transduced cells, again most preferably replication incompetent tumor cells, or incorporated into microparticulate vehicles such as polymeric microspheres.",UNIV JOHNS HOPKINS;;BREM HENRY;;PARDOLL DREW M;;THOMPSON REID C;;JAFFEE ELIZABETH M;;LEONG KAM W;;EWEND MATTHEW G,BREM HENRY;;PARDOLL DREW M;;THOMPSON REID C;;JAFFEE ELIZABETH M;;LEONG KAM W;;EWEND MATTHEW G,,https://lens.org/171-824-589-278-331,Patent Application,yes,0,16,5,5,0,A61K9/0085;;A61K39/0011;;A61K48/00;;A61P35/00;;A61K39/0011,A61K9/00;;A61K35/12;;A61K9/50;;A61K38/00;;A61K39/00;;A61K47/30;;A61K48/00;;A61P35/00,,8,8,051-030-157-212-288;;024-188-635-849-779;;051-613-770-841-781;;017-145-308-581-003;;035-428-926-783-801;;087-879-787-031-413;;031-656-787-332-056;;063-314-702-366-54X,7621236;;10.1006/jsre.1995.1034;;7861776;;8564954;;10.1038/bjc.1996.308;;pmc2074618;;8679459;;8423625;;10.1093/jnci/85.3.207;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;8261390;;9041459;;10.1097/00002371-199611000-00004,"PIPPIN ET AL: ""LOCAL IL-4 DELIVERY ENHANCES IMMUNE REACTIVITY TO MURINE TUMORS: GENE THERAPY IN COMBINATION WITH IL2"", CANCER GENE THERAPY, vol. 1, no. 1, 1994, pages 35 - 42, XP002057835;;PAPPO ET AL: ""ADMINISTRATION OF SYSTEMIC OR LOCAL INTERLEUKIN-2 ENHANCES THE ANTI-TUMOR EFFECTS OF INTERLEUKIN-12 GENE THERAPY"", JOURNAL OF SURGICAL RESEARCH, vol. 58, 1995, pages 218 - 226, XP002057836;;VAGLIANI ET AL: ""INTERLEUKIN 12 POTENTIATES THE CURATIVE EFFECT OF A VACCINE BASED ON INTERLEUKIN 2-TRANSDUCED TUMOR CELLS"", CANCER RESEARCH, vol. 56, 1 February 1996 (1996-02-01), pages 467 - 470, XP002057837;;HOLLINGSWORTH ET AL: ""THE EFFECT OF COMBINED EXPRESSSION OF INTERLEUKIN 2 AND INTERLEUKIN 4 ON THE TUMORIGENICITY AND TREATMENT OF B16F10 MELANOMA"", BRITISH JOURNAL OF CANCER, vol. 74, July 1996 (1996-07-01), pages 6 - 15, XP002057838;;BELLDEGRUN ET AL: ""HUMAN RENAL CARCINOMA LINE TRANSFECTED WITH INTERLEUKIN-2 AND/OR INTERFERON ALPHA GENE(S): IMPLICATIONS FOR LIVE CANCER VACCINES"", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 85, 1993, pages 207 - 216, XP002057839;;DRANOFF ET AL: ""VACCINATION WITH IRRADIATED TUMOR CELLS ENGINEERED TO SECRETE MURINE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR STIMULATES POTENT, SPECIFIC, AND LONG-LASTING ANTI-TUMOR IMMUNITY"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES,USA, vol. 90, 1993, pages 3539 - 3543, XP002057840;;GOLUMBEK ET AL: ""CONTROLLED RELEASE, BIODEGRADABLE CYTOKINE DEPOTS: A NEW APPROACH IN CANCER VACCINE DESIGN"", CANCER RESEARCH, vol. 53, 1993, pages 5841 - 5844, XP002057841;;THOMPSON ET AL: ""SYSTEMIC AND LOCAL PARACRINE CYTOKINE THERAPIES USING TRANSDUCED TUMOR CELLS ARE SYNERGISTIC IN TREATING INTRACRANIAL TUMORS"", JOURNAL OF IMMUNOTHERAPY, vol. 19, no. 6, November 1996 (1996-11-01), pages 405 - 413, XP002057842",PENDING
